Introduction
SARS
SEVERE ACUTE RESPIRATORY SYNDROME
Sotrovimab is an Fc-engineered pan-sarbecovirus human monoclonal antibody, which was developed for the treatment of COVID-19 from a parental antibody isolated from a survivor of the severe acute respiratory syndrome (SARS) outbreak in 2003 [The Globally, COVID-19 is associated with significant clinical, public health and economic burden, leading to missed school and work to recover from illness [In COMET-ICE, the FLU-PRO Plus questionnaire was used to assess symptoms and impacts of COVID-19, along with the Short Form-12 (SF-12) Hybrid questionnaire (SF-12 plus the full SF-36 domains of vitality and physical role) to measure self-reported functional health and wellbeing, and the validated, patient-reported Work Productivity and Activity Impairment (WPAI) tool to quantitively assess absenteeism, presenteeism, work productivity loss, and activity impairment. Here we report the results for these PRO assessments in the COMET-ICE trial up to Day 29.